EGFR and colorectal cancer: Although the EGFR and K-RAS mutations are mutually exclusive in clinical observations of NSCLC and colorectal cancer, they have been found to co-exist in PDAC despite EGFR mutation only accounting for less than 3% of PDAC [62,63].